ArticleAnnals of hematology2026
Safety, pharmacokinetics, and preliminary efficacy of hetrombopag in pediatric patients with aplastic anemia: A pilot study.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Hetrombopag, a novel thrombopoietin receptor agonist (TPO-RA), has demonstrated efficacy in adult patients with aplastic anemia (AA), but its role in pediatric AA patients remains unknown. This study evaluated the safety, pharmacokinetic (PK) profile, and preliminary efficacy of hetrombopag in pediatric AA. This pilot study enrolled pediatric patients with AA who were ineligible for hematopoietic stem cell transplantation. Patients received hetrombopag in combination with immunosuppressive therapy. Safety, PK parameters, and hematologic response (HR) rates at 3 and 6 months were analyzed. A total of 21 pediatric patients were enrolled, including six patients aged 1-5 years, nine patients aged 6-11 years, and six patients aged 12-17 years. Among them, 18 patients had severe AA and 3 had non-severe AA. The most common treatment-related adverse events were transaminase increased (33.3%) and blood bilirubin increased (14.3%). PK analysis revealed age-dependent variability, with the 6-11-year cohort exhibiting the highest inter-individual variability and excessive plasma drug exposure. Among patients with SAA, as defined by the Chinese guideline criteria, the HR rate at 3 months was 55.6% (10/18; 95% CI: 21.5-69.2), and the complete response (CR) rate was 5.6% (1/18; 95% CI: 0.1-27.3). By 6 months, the HR rate had increased to 72.2% (13/18; 95% CI: 46.5-90.3), and the CR rate to 22.2% (4/18; 95% CI: 6.4-47.6). Hetrombopag, in combination with IST, demonstrated a favorable safety profile, preliminary efficacy, and age-dependent PK variability in pediatric AA. These findings support further investigation into individualized dosing strategies to optimize therapeutic outcomes in this population. The trial was registered prospectively at the Chinese Clinical Trial Registry (ChiCTR2300068312) on February 14, 2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.